These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 17135786)
1. A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Hasegawa N; Mizutani K; Suzuki T; Deguchi T; Nozawa Y Urol Int; 2006; 77(4):347-54. PubMed ID: 17135786 [TBL] [Abstract][Full Text] [Related]
2. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014 [TBL] [Abstract][Full Text] [Related]
3. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980 [TBL] [Abstract][Full Text] [Related]
4. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Akao Y; Banno Y; Nakagawa Y; Hasegawa N; Kim TJ; Murate T; Igarashi Y; Nozawa Y Biochem Biophys Res Commun; 2006 Apr; 342(4):1284-90. PubMed ID: 16516161 [TBL] [Abstract][Full Text] [Related]
5. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Wang XZ; Beebe JR; Pwiti L; Bielawska A; Smyth MJ Cancer Res; 1999 Nov; 59(22):5842-8. PubMed ID: 10582708 [TBL] [Abstract][Full Text] [Related]
6. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones]. Yan XD; Pan LY Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753 [TBL] [Abstract][Full Text] [Related]
8. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Sinha R; Pinto JT; Facompre N; Kilheffer J; Baatz JE; El-Bayoumy K Nutr Cancer; 2008; 60(2):267-75. PubMed ID: 18444160 [TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Ornstein DK; Gillespie JW; Paweletz CP; Duray PH; Herring J; Vocke CD; Topalian SL; Bostwick DG; Linehan WM; Petricoin EF; Emmert-Buck MR Electrophoresis; 2000 Jun; 21(11):2235-42. PubMed ID: 10892734 [TBL] [Abstract][Full Text] [Related]
10. Differential proteome analysis of conditioned medium of BPH-1 and LNCaP cells. Chen WZ; Pang B; Yang B; Zhou JG; Sun YH Chin Med J (Engl); 2011 Nov; 124(22):3806-9. PubMed ID: 22340245 [TBL] [Abstract][Full Text] [Related]
11. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454 [TBL] [Abstract][Full Text] [Related]
12. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641 [TBL] [Abstract][Full Text] [Related]
13. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Liu Y; Liu H; Han B; Zhang JT Cancer Res; 2006 Mar; 66(6):3248-55. PubMed ID: 16540677 [TBL] [Abstract][Full Text] [Related]
14. 14-3-3sigma is down-regulated in human prostate cancer. Urano T; Takahashi S; Suzuki T; Fujimura T; Fujita M; Kumagai J; Horie-Inoue K; Sasano H; Kitamura T; Ouchi Y; Inoue S Biochem Biophys Res Commun; 2004 Jul; 319(3):795-800. PubMed ID: 15184053 [TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. Sardana G; Jung K; Stephan C; Diamandis EP J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523 [TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of prostate cancer metastasis-derived prostasomes. Ronquist KG; Ronquist G; Larsson A; Carlsson L Anticancer Res; 2010 Feb; 30(2):285-90. PubMed ID: 20332430 [TBL] [Abstract][Full Text] [Related]
18. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731 [TBL] [Abstract][Full Text] [Related]
19. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. Yan XD; Pan LY; Yuan Y; Lang JH; Mao N J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733 [TBL] [Abstract][Full Text] [Related]
20. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Chang JY; Liu JF; Juang SH; Liu TW; Chen LT Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]